100 related articles for article (PubMed ID: 35238345)
21. Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis.
Martinaud C; Desterke C; Konopacki J; Vannucchi AM; Pieri L; Guglielmelli P; Dupriez B; Ianotto JC; Boutin L; Lataillade JJ; Le Bousse-Kerdilès MC
Genom Data; 2015 Sep; 5():1-2. PubMed ID: 26484208
[TBL] [Abstract][Full Text] [Related]
22. New Markers of Disease Progression in Myelofibrosis.
Campanelli R; Massa M; Rosti V; Barosi G
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771488
[TBL] [Abstract][Full Text] [Related]
23. Complete resolution of primary myelofibrosis in an infant with steroids and hydroxyurea.
Khera S; Misra P; Singh K; Tripathi P
BMJ Case Rep; 2023 Nov; 16(11):. PubMed ID: 37993140
[TBL] [Abstract][Full Text] [Related]
24. Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review.
Butnariu I; Antonescu-Ghelmez D; Moraru A; Anghel DN; Cojocaru FM; Tuță S; Ciobanu AM; Antonescu F
Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38276052
[TBL] [Abstract][Full Text] [Related]
25. Neuropilin2 in Mesenchymal Stromal Cells as a Potential Novel Therapeutic Target in Myelofibrosis.
Vosbeck K; Förster S; Mayr T; Sahu A; Haddouti EM; Al-Adilee O; Körber RM; Bisht S; Muders MH; Nesic S; Buness A; Kristiansen G; Schildberg FA; Gütgemann I
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38792002
[TBL] [Abstract][Full Text] [Related]
26. Systematic dissection of coordinated stromal remodeling identifies Sox10
Sarkaria SM; Zhou J; Bao S; Zhao W; Fang Y; Que J; Bhagat G; Zhang C; Ding L
Cell Stem Cell; 2023 Jun; 30(6):832-850.e6. PubMed ID: 37267917
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow findings post allogeneic transplant for myeloproliferative neoplasms and chronic myelomonocytic leukemia with increased fibrosis.
Gupta S; Courville EL
Lab Med; 2024 Apr; ():. PubMed ID: 38603517
[TBL] [Abstract][Full Text] [Related]
28. Aplastic Anemia Mimicking Myelofibrosis: A Diagnostic Dilemma.
Patel N; Mirza H; Bai P; Shah V; Patel H; Khealani M; Kukreja G; Obulareddy SJ
Cureus; 2023 Nov; 15(11):e49445. PubMed ID: 38149134
[TBL] [Abstract][Full Text] [Related]
29. Quantitative interpretation of bone marrow biopsies in MPN-What's the point in a molecular age?
Ryou H; Lomas O; Theissen H; Thomas E; Rittscher J; Royston D
Br J Haematol; 2023 Nov; 203(4):523-535. PubMed ID: 37858962
[TBL] [Abstract][Full Text] [Related]
30. [A case of prefibrotic primary myelofibrosis in a child with type-Ⅰ CALR gene mutation].
Li SQ; Zhao YQ; Zhao XL; Wang XG; Li SB; Song LL; Zhou YJ; Zang WT; Hao T; Yao XJ
Zhonghua Er Ke Za Zhi; 2023 Oct; 61(10):928-930. PubMed ID: 37803861
[TBL] [Abstract][Full Text] [Related]
31. Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC-PM.
Guerra M; Pasquer H; Daltro de Oliveira R; Soret-Dulphy J; Maslah N; Zhao LP; Marcault C; Cazaux M; Gauthier N; Verger E; Parquet N; Vainchenker W; Raffoux E; Giraudier S; Cassinat B; Kiladjian JJ; Benajiba L
Am J Hematol; 2024 Apr; 99(4):741-744. PubMed ID: 38279562
[TBL] [Abstract][Full Text] [Related]
32. Type 1 CALR mutation allele frequency correlates with CD34/CXCR4 expression in myelofibrosis-type megakaryocyte dysplasia: A mechanism of disease progression?
Barosi G; Campanelli R; Catarsi P; Abbà C; Carolei A; Massa M; Gale RP; Rosti V
Blood Cancer J; 2024 Jan; 14(1):18. PubMed ID: 38253566
[No Abstract] [Full Text] [Related]
33. Concerns regarding myelofibrosis-type megakaryocyte dysplasia.
Cai Y; Wang Y; Yang J; Zhu Z
Leukemia; 2024 Feb; 38(2):467-468. PubMed ID: 38263434
[No Abstract] [Full Text] [Related]
34. A rare case of primary myelofibrosis with novel cytogenetic abnormality - deletion 4q25.
Chattopadhyay D; Hajra S; Chandra H; Nath UK
Indian J Pathol Microbiol; 2024 Mar; ():. PubMed ID: 38563691
[No Abstract] [Full Text] [Related]
35. Is Treatment for Cytopenic Myelofibrosis Still an Unmet Clinical Need?
Caduc MJ; Koschmieder S
Hemasphere; 2023 Nov; 7(11):e982. PubMed ID: 37928624
[No Abstract] [Full Text] [Related]
36. [How I treat primary myelofibrosis].
Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2019 Mar; 40(3):179-181. PubMed ID: 30929381
[No Abstract] [Full Text] [Related]
37. Myelofibrosis.
Passamonti F; Mora B
Blood; 2023 Apr; 141(16):1954-1970. PubMed ID: 36416738
[TBL] [Abstract][Full Text] [Related]
38. Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in Myelofibrosis.
Varricchio L; Hoffman R
Front Oncol; 2022; 12():906698. PubMed ID: 35646681
[TBL] [Abstract][Full Text] [Related]
39. How I Diagnose Primary Myelofibrosis.
Prakash S; Orazi A
Am J Clin Pathol; 2022 Apr; 157(4):518-530. PubMed ID: 35238345
[TBL] [Abstract][Full Text] [Related]
40. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
Rumi E; Cazzola M
Blood; 2017 Feb; 129(6):680-692. PubMed ID: 28028026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
